Does a higher arachidonic acid to EPA ratio indicate greater pro-inflammatory lipid mediator potential?

The arachidonic acid (AA) to eicosapentaenoic acid (EPA) ratio is a well-established biochemical indicator used to assess the inflammatory potential of an individual’s lipid profile. This ratio reflects the competition between omega-6 and omega-3 fatty acids for common metabolic pathways, ultimately determining the balance between pro-inflammatory and pro-resolving signaling molecules.

Mechanistic basis of substrate competition

The AA:EPA ratio dictates the inflammatory "tone" of a cell by controlling which substrates are available to cyclooxygenase (COX) and lipoxygenase (LOX) enzymes.

• Phospholipid Displacement: AA and EPA are stored at the same locations in cell membrane phospholipids (the sn-2 position). Because they compete for these sites, the ratio in the blood directly reflects their relative abundance in tissues.
• Enzymatic Flux: When a cell is activated, Phospholipase A2 (PLA2) releases these fatty acids. A higher AA:EPA ratio means more AA is available to COX-2 and 5-LOX enzymes. AA is the preferred substrate for these enzymes, possessing a lower Km (higher affinity) and higher kcat (turnover rate) compared to EPA.
• Mediator Polarity: High AA availability leads to the dominant production of 2-series eicosanoids (e.g., PGE2) and 4-series leukotrienes (e.g., LTB4), which are potent drivers of pain, swelling, and leukocyte recruitment. In contrast, EPA serves as the precursor for less potent 3-series analogs and anti-inflammatory E-series resolvins.

Clinical and diagnostic significance

The AA:EPA ratio is utilized in research and clinical practice to gauge systemic inflammatory potential and the risk of chronic disease.

• Inflammatory Biomarker: Studies demonstrate that a high AA:EPA ratio is associated with elevated systemic markers such as C-reactive protein (CRP) and Interleukin-6 (IL-6). For example, in patients with cardiovascular disease, a lower ratio (achieved via EPA supplementation) is strongly correlated with improved arterial health and reduced inflammatory signaling.
• Supplementation Response: Clinical trials show that lowering the ratio through fish oil or purified EPA leads to a measurable shift in the eicosanoid profile. Decreases in the ratio have been shown to reduce LTB4 production in neutrophils by up to 30-50% in healthy volunteers and patients with inflammatory conditions.
• Target Ranges: While higher ratios (e.g., >10) are consistently linked to pro-inflammatory states, there is no universal clinical "gold standard" target. However, many practitioners aim for a ratio between 1.5 and 3 to reflect a balanced inflammatory potential.

Bottom line

A higher AA:EPA ratio is a scientifically validated index of pro-inflammatory potential. It reflects a shift in membrane composition that favors the synthesis of potent inflammatory eicosanoids over less active or pro-resolving mediators. Lowering this ratio through dietary or supplemental EPA effectively reshapes the lipid environment to support the resolution of inflammation.